LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 5 von insgesamt 5

Suchoptionen

  1. Artikel ; Online: Perioperative use of cefazolin without preliminary skin testing in patients with reported penicillin allergy.

    Kuruvilla, Merin / Wolf, Francis / Sexton, Marybeth / Wiley, Zanthia / Thomas, Jamie

    Surgery

    2018  Band 165, Heft 2, Seite(n) 486–496

    Mesh-Begriff(e) Antibiotic Prophylaxis ; Cefazolin ; Drug Hypersensitivity ; Humans ; Penicillins ; beta-Lactams
    Chemische Substanzen Penicillins ; beta-Lactams ; Cefazolin (IHS69L0Y4T)
    Sprache Englisch
    Erscheinungsdatum 2018-07-10
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 202467-6
    ISSN 1532-7361 ; 0039-6060
    ISSN (online) 1532-7361
    ISSN 0039-6060
    DOI 10.1016/j.surg.2018.05.054
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uk I Zs.129: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: A Streamlined Approach to Optimize Perioperative Antibiotic Prophylaxis in the Setting of Penicillin Allergy Labels.

    Kuruvilla, Merin / Sexton, Marybeth / Wiley, Zanthia / Langfitt, Terry / Lynde, Grant C / Wolf, Francis

    The journal of allergy and clinical immunology. In practice

    2019  Band 8, Heft 4, Seite(n) 1316–1322

    Abstract: Background: Patients with penicillin allergy labels often receive alternative antibiotics for perioperative prophylaxis, as opposed to first-line cephalosporins (cefazolin/cefuroxime). Provider misconceptions about the risk of cross-reactivity likely ... ...

    Abstract Background: Patients with penicillin allergy labels often receive alternative antibiotics for perioperative prophylaxis, as opposed to first-line cephalosporins (cefazolin/cefuroxime). Provider misconceptions about the risk of cross-reactivity likely drive this prescribing behavior, which is problematic because of its association with increased risk of surgical-site infections.
    Objective: To develop, implement, and assess the safety of a streamlined approach to perioperative antibiotic selection for surgical patients with a penicillin allergy label, to reduce the use of second-line antibiotics.
    Methods: A multidisciplinary task force developed an institutional algorithm for antibiotic selection in penicillin-allergic surgical patients. The percentage of patients receiving a first-line cephalosporin was compared before and after algorithm utilization. The safety of this approach was assessed via chart review of all patients who received epinephrine or diphenhydramine in the operating room, or diphenhydramine within 24 hours postoperatively, assessing for any adverse reactions to cephalosporin administration.
    Results: Between September 2016 and May 2019, 9.3% of surgical patients had documented penicillin allergy (n = 2296). At baseline, 22% of these patients received a cephalosporin, with an increase to more than 80% after algorithm implementation (P < .0001). Among 551 patients with penicillin allergy label who received a cephalosporin after algorithm implementation, no immediate allergic reactions requiring epinephrine were identified; 1 patient had a delayed rash that did not require cephalosporin discontinuation. Three patients received diphenhydramine for "itching" without rash in the setting of concomitant narcotic administration.
    Conclusions: Using a streamlined algorithm, we were able to significantly reduce the use of second-line antibiotics in penicillin-allergic surgical patients without severe adverse reactions.
    Mesh-Begriff(e) Anti-Bacterial Agents/adverse effects ; Antibiotic Prophylaxis ; Cephalosporins ; Drug Hypersensitivity/drug therapy ; Humans ; Penicillins/adverse effects
    Chemische Substanzen Anti-Bacterial Agents ; Cephalosporins ; Penicillins
    Sprache Englisch
    Erscheinungsdatum 2019-12-28
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2019.12.016
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 7086: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel: Human Adenovirus 11 in 2 Renal Transplant Recipients: Suspected Donor-Derived Infection.

    Sherman, Amy C / Lu, Xiaoyan / Schneider, Eileen / Langston, Amelia / Ellis, Carla L / Pastan, Stephen / Bhatnagar, Julu / Reagan-Steiner, Sarah / Annambhotla, Pallavi / Lindstrom, Stephen / Mehta, Aneesh / Pouch, Stephanie M / Sexton, Marybeth E

    Open forum infectious diseases

    2021  Band 8, Heft 3, Seite(n) ofab092

    Abstract: Background: Human adenovirus (HAdV) infections can lead to high mortality in solid organ transplant (SOT) recipients, with rare reports of donor-derived infection.: Methods: Two renal transplant recipients with HAdV-11 infection who received kidneys ... ...

    Abstract Background: Human adenovirus (HAdV) infections can lead to high mortality in solid organ transplant (SOT) recipients, with rare reports of donor-derived infection.
    Methods: Two renal transplant recipients with HAdV-11 infection who received kidneys from the same donor are described. Whole-genome sequencing (WGS) was performed.
    Results: WGS showed 100% nucleotide sequence identity for the 2 HAdV-11 isolates. The patients presented with distinct clinical syndromes, and both were treated with brincidofovir.
    Conclusions: Donor-derived HAdV infection is presumed to be low; however, disseminated HAdV in SOT recipients can be severe, and clinicians should be aware of the clinical course and treatment options.
    Sprache Englisch
    Erscheinungsdatum 2021-02-25
    Erscheinungsland United States
    Dokumenttyp Case Reports
    ZDB-ID 2757767-3
    ISSN 2328-8957
    ISSN 2328-8957
    DOI 10.1093/ofid/ofab092
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  4. Artikel: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.

    Edara, Venkata-Viswanadh / Manning, Kelly E / Ellis, Madison / Lai, Lilin / Moore, Kathryn M / Foster, Stephanie L / Floyd, Katharine / Davis-Gardner, Meredith E / Mantus, Grace / Nyhoff, Lindsay E / Bechnak, Sarah / Alaaeddine, Ghina / Naji, Amal / Samaha, Hady / Lee, Matthew / Bristow, Laurel / Hussaini, Laila / Ciric, Caroline Rose / Nguyen, Phuong-Vi /
    Gagne, Matthew / Roberts-Torres, Jesmine / Henry, Amy R / Godbole, Sucheta / Grakoui, Arash / Sexton, Marybeth / Piantadosi, Anne / Waggoner, Jesse J / Douek, Daniel C / Anderson, Evan J / Rouphael, Nadine / Wrammert, Jens / Suthar, Mehul S

    bioRxiv : the preprint server for biology

    2021  

    Abstract: The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike ...

    Abstract The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naïve vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.
    Sprache Englisch
    Erscheinungsdatum 2021-12-22
    Erscheinungsland United States
    Dokumenttyp Preprint
    DOI 10.1101/2021.12.20.473557
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

  5. Artikel ; Online: mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant

    Edara, Venkata-Viswanadh / Manning, Kelly E / Ellis, Madison / Lai, Lilin / Moore, Kathryn M / Foster, Stephanie L / Floyd, Katharine / Davis-Gardner, Meredith E / Mantus, Grace / Nyhoff, Lindsay E / Bechnack, Sarah / Alaaeddine, Ghina / Naji, Amal / Samaha, Hady / Lee, Matthew / Bristow, Laurel / Hussaini, Laila / Ciric, Caroline Rose / Nguyen, Phuong-Vi /
    Gagne, Matthew / Roberts-Torres, Jesmine / Henry, Amy R / Godbole, Sucheta / Grakoui, Arash / Sexton, Marybeth / Piantadosi, Anne / Waggoner, Jesse J / Douek, Daniel C / Anderson, Evan J / Rouphael, Nadine / Wrammert, Jens / Suthar, Mehul S

    bioRxiv

    Abstract: The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike ...

    Abstract The BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines generate potent neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the global emergence of SARS-CoV-2 variants with mutations in the spike protein, the principal antigenic target of these vaccines, has raised concerns over the neutralizing activity of vaccine-induced antibody responses. The Omicron variant, which emerged in November 2021, consists of over 30 mutations within the spike protein. Here, we used an authentic live virus neutralization assay to examine the neutralizing activity of the SARS-CoV-2 Omicron variant against mRNA vaccine-induced antibody responses. Following the 2nd dose, we observed a 30-fold reduction in neutralizing activity against the omicron variant. Through six months after the 2nd dose, none of the sera from naive vaccinated subjects showed neutralizing activity against the Omicron variant. In contrast, recovered vaccinated individuals showed a 22-fold reduction with more than half of the subjects retaining neutralizing antibody responses. Following a booster shot (3rd dose), we observed a 14-fold reduction in neutralizing activity against the omicron variant and over 90% of boosted subjects showed neutralizing activity against the omicron variant. These findings show that a 3rd dose is required to provide robust neutralizing antibody responses against the Omicron variant.
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2021-12-22
    Verlag Cold Spring Harbor Laboratory
    Dokumenttyp Artikel ; Online
    DOI 10.1101/2021.12.20.473557
    Datenquelle COVID19

    Volltext online

    Kategorien

    Fernleihe an ZB MED

    Sie können sich den gewünschten Titel als lokale Nutzerin oder lokaler Nutzer von ZB MED direkt an den Standort Köln schicken lassen.

Zum Seitenanfang